wire
Sep 13, 2026

The End of Big Pharma's Reign? Trump Secures 9 New Deals in Aggressive Expansion of 'Most-Favored-Nation' Strategy

For decades, American patients have shouldered the crushing burden of the highest prescription drug prices globally, essentially subsidizing the medical costs of other developed nations. However, a seismic shift is underway in the healthcare landscape. In a historic move designed to dismantle pharmaceutical monopolies, President Donald Trump has officially expanded his "Most-Favored-Nation" (MFN) drug pricing strategy, securing nine new landmark agreements with mid-sized drug manufacturers. This aggressive executive action promises to save American taxpayers and patients billions of dollars, but it has simultaneously ignited a fierce political firestorm in Washington.

The Core of the Most-Favored-Nation (MFN) Strategy

Other posts